In this episode of the China biopharma English-language podcast, Xu Hu

The Pink Sheet stories related to this episode:

CAR-T Guidelines Signal China’s Next

CAR-Ts Win Big In New China Drug

A legal firm’s perspective on how the UK should evolve its medtech regulatory system, global harmonization and opportunities to embed best practice AI.

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年3月27当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。

本期要闻: 默克公司力推Terns及其他交易；勃林格殷格翰对欧洲创新环境不佳的警示；科伦与默克的协议如何改变了中国的交易格局；神经科学研发重振旗鼓；以及美国新的低密度脂蛋白胆固醇（LDL-C）指南与药物成本。

In this episode of HBW Insight’s Over the Counter, we’re digging into one of the most talked‑about themes in consumer health right now: longevity.

Audio roundup of selected biopharma industry content from Scrip over the business week ended Mar.27, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – Merck’s case for Terns and more deals; Boehringer’s warning on innovation-unfriendly Europe; how Kelun-Merck pact changed China deal-making;

Story Link :

Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs consider US Food and Drug Administration Commissioner Martin Makary’s first year in office, including the issues that shaped his tenure (:32), his biggest policy accomplishments (14:12), issues that could emerge in his second year (19:35), and when Makary’s term could end (22:52).

#pharma #business #FDA

More On These Topics From The Pink Sheet

US FDA Commissioner Makary’s ‘Bold’ Year 1 Reforms Clouded By Staff Churn, Process Issues: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/us-fda-commissioner-makarys-bold-year-1-reforms-clouded-by-staff-churn-process-issues-BM6PHO3AWNBWXHL5UAJI4YE7TQ/

His Own Words: FDA Commissioner Martin Makary On His First Year Achievements And Challenges: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/his-own-words-fda-commissioner-martin-makary-on

Lupin’s CEO Vinita Gupta and managing director Nilesh Gupta speak with Citeline’s senior editor Vibha Ravi about their plans for first-in-class and best-in-class assets including GLP-1 receptor agonists, the defining influence of their father D B Gupta on them, as well as the company’s ethos and future growth strategy.